ClinicalTrials.gg
Not yet recruitingNCT07856823Updated Oct 5, 2026

High-Resolution Measurements of Diet-Microbiome Interactions

An interventional study of Inulin and Low-fiber control breakfast shake in IBS (Irritable Bowel Syndrome), sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Stanford University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.

Planned enrollment
179th of 287
40 · median 61
Started
2026
with 17 others
No phase
134 of 344
21 open now
Primary completion
2028-10
later than 42 of 48 live
Registered
342nd of 344
by date

Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 179th largest by planned enrollment of the 287 interventional ones that give a count, is one of 18 that started in 2026, is one of 134 with no phase, reaches primary completion later than 42 of the 48 other live ones, and was the 342nd registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Irritable Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to characterize regional intestinal fermentation physiology and determine how the response to fermentable dietary fiber differs between healthy individuals and individuals with irritable bowel syndrome (IBS). The study will use ingestible capsule technologies to directly measure intestinal gases and regional microbiome composition following low-fiber and high-fiber meal challenges.

The main questions it aims to answer are:

Does the change in regional intestinal gas levels following a fermentable-fiber challenge differ between participants with IBS and healthy controls? How are regional intestinal gas dynamics associated with microbiome composition, breath gases, serum short-chain fatty acids, glucose dynamics, metabolites, and gastrointestinal symptoms?

Researchers will compare participants with IBS to healthy controls to determine whether intestinal fermentation responses to dietary fiber differ between these populations.

Participants will:

Complete two study visits approximately one week apart. At one visit, participants will receive a low-fiber control meal, and at the other visit, they will receive the same base meal containing 15 g of inulin. The order of the two meals will be assigned at random.

Swallow an Atmo gas-sensing capsule to measure intestinal H2, CO2, and O2 and a CapScan capsule to collect regional intestinal fluid for microbiome analysis.

Undergo serial blood and breath sampling and gastrointestinal symptom assessments during each 8-hour study visit.

Complete stool and urine collections, dietary assessment, and continuous glucose monitoring before and/or after the study visits.

Read the detailed description

Irritable Bowel Syndrome (IBS) affects an estimated 25-45 million people in the United States, accounts for roughly 20-40% of gastroenterology visits, and imposes a major societal burden, with annual U.S. costs estimated at approximately $1.7-$10 billion in direct medical spending and approximately $20 billion in indirect costs from lost productivity (Hulisz 2004; Leong et al. 2003; Canavan et al. 2014). Despite this burden, IBS remains poorly understood, and no validated biochemical diagnostic or curative therapy currently exists (Lacy et al. 2021; Kim et al. 2017).

In most individuals, a high-fiber diet supports a healthy microbiome and improves health outcomes without adverse symptoms (Fu et al. 2022). In patients with IBS, however, fermentable fiber is known to worsen symptoms such as bloating, flatulence, and abdominal pain; patients are often advised to restrict fermentable fiber intake (e.g., a low-FODMAP diet), and antibiotics are sometimes used therapeutically to suppress fermentation (Halmos et al. 2014; Lacy et al. 2021). These clinical observations motivate the mechanistic hypothesis underlying this protocol: that IBS symptoms may arise, at least in part, from disordered microbial fermentation and impaired intestinal gas handling.

Progress toward this goal has been limited by the absence of direct clinical tools capable of quantifying fermentation physiology in vivo and by intestinal region. Current clinical testing (e.g., hydrogen/methane breath testing) provides only an indirect, systemic proxy for fermentation and remains variably standardized (Rezaie et al. 2017; Pitcher et al. 2022).

The human intestine is more than 30 feet in length and is home to regionally distinct microbial communities that closely track local gut physiology (Martinez-Guryn et al. 2019). Recently developed non-invasive capsule-based microbiome sampling has shown that the small intestine and proximal colon harbor communities that are distinct from stool and disproportionately altered in IBS (Shalon et al. 2023; Leite et al. 2020; Chung et al. 2016).

This protocol leverages two complementary ingestible capsule technologies - a real-time gas-sensing capsule (Atmo) and a regional fluid/microbiome-sampling capsule (CapScan) - together with stool, urine, breath, and blood-based measurements, to establish regional gas production and consumption profiles in healthy individuals and patients with IBS.

The Healthy and IBS cohorts are defined by baseline clinical status and are not randomized. Within each cohort, participants undergo a randomized two-period crossover of meal order. Each participant receives both the low-fiber control meal and the 15 g inulin meal, with the order assigned at random.

03

Conditions studied

  • IBS (Irritable Bowel Syndrome)

Keywords

  • Irritable Bowel Syndrome
  • IBS
  • Inulin
  • Regional Microbiome
  • Dietary Fiber
  • Intestinal Microbiome
  • Intestinal Fermentation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years.
  2. Able to provide written .
  3. Able and willing to swallow capsules and complete all study procedures.
  4. For the Healthy cohort: no history of a diagnosed chronic GI disorder and no ongoing GI symptoms warranting clinical evaluation.
  5. For the IBS cohort: meets Rome IV diagnostic criteria for IBS, with a prior clinical hydrogen/methane breath test on record sufficient to assign a breath-test subtype.
  6. Willing and able to complete a virtual (Zoom) screening visit and two in-clinic study visits approximately one week apart.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected gastrointestinal stricture or physiological/mechanical gastrointestinal obstruction.
  2. Gastrointestinal fistula.
  3. Dysphagia or other swallowing disorder affecting the ability to swallow food, pills, or capsules.
  4. Gastrointestinal surgery within the past 3 months.
  5. Prior gastrointestinal surgery that alters luminal anatomy (e.g., bowel resection or bariatric surgery).
  6. Diverticulitis.
  7. Gastric bezoar.
  8. Radiation enteritis.
  9. Pacemaker or other implanted or portable electromechanical medical device.
  10. Pregnancy or breastfeeding.
  11. ≥40 kg/m².
  12. Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to enrollment.
  13. Use of proton-pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole [Nexium®]) within 7 days prior to the study procedure.
  14. Use of histamine blockers, motility-altering medications, narcotic analgesics, or anticholinergic medications within 3 days prior to the study procedure.
  15. Use of antiemetics/5-HT3 antagonists, macrolide antibiotics, or 5-HT4-modulating medications within 2 days prior to the study procedure.
  16. Use of antacids (e.g., Gaviscon®, Mylanta®, TUMS) within 1 day prior to the study procedure.
  17. Diabetes or use of medications affecting glucose handling.
  18. Known allergy or intolerance to inulin or other study meal components.
  19. Current participation in another interventional study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Healthy controls

    The Healthy cohort consists of individuals without a diagnosed chronic gastrointestinal disorder or ongoing gastrointestinal symptoms warranting clinical evaluation. Participants complete two study visits approximately one week apart and receive both meal conditions in randomized order: low-fiber control followed by 15 g of inulin, or 15 g of inulin followed by low-fiber control. At each visit, participants consume the assigned standardized breakfast shake with the Atmo gas-sensing capsule at t=0 and ingest the CapScan regional sampling capsule at t=4 hours.

    Dietary Supplement: Inulin · Other: Low-fiber control breakfast shake · Device: Atmo Gas-Sensing Capsule · Device: CapScan Regional Fluid-Sampling Capsule

  • Experimental
    Irritable Bowel Syndrome (IBS)

    The IBS cohort consists of individuals who meet Rome IV diagnostic criteria for irritable bowel syndrome. Participants complete two study visits approximately one week apart and receive both meal conditions in randomized order: low-fiber control followed by 15 g of inulin, or 15 g of inulin followed by low-fiber control. At each visit, participants consume the assigned standardized breakfast shake with the Atmo gas-sensing capsule at t=0 and ingest the CapScan regional sampling capsule at t=4 hours.

    Dietary Supplement: Inulin · Other: Low-fiber control breakfast shake · Device: Atmo Gas-Sensing Capsule · Device: CapScan Regional Fluid-Sampling Capsule

Interventions

  • Dietary supplementInulin

    Participants consume a standardized breakfast shake containing 15 g of inulin at one of the two study visits, according to the randomized meal sequence. At the other visit, they consume the same base shake without added inulin as the low-fiber control. Visits occur approximately one week apart.

  • OtherLow-fiber control breakfast shake

    Participants consume the standardized low-fiber base breakfast shake without added inulin at one of the two study visits, according to the randomized meal sequence. This condition serves as the within-participant control. Visits occur approximately one week apart.

  • DeviceAtmo Gas-Sensing Capsule

    At each of the two study visits, participants will swallow one Atmo gas-sensing capsule with the assigned standardized breakfast shake at t=0. As it transits the gastrointestinal tract, the wireless capsule records regional luminal hydrogen (H2), carbon dioxide (CO2), oxygen-related signals, temperature, and transit-related data. Data are transmitted by radiofrequency to a wearable receiver for analysis. Capsule passage will be monitored after each visit.

    Also known as: Atmo Gas Capsule System

  • DeviceCapScan Regional Fluid-Sampling Capsule

    At each of the two study visits, participants will swallow one CapScan capsule at t=4 hours. CapScan is a single-use, passive ingestible device that collects regional gastrointestinal luminal fluid as it transits the intestine. The collected samples will be used for ex vivo microbiome and multiomic analyses. The device passes in the stool and is retrieved by the participant using the provided retrieval materials for subsequent processing.

    Also known as: CapScan, Envivo Bio Collection Device

06

What researchers measure

Primary outcomes

  1. Successful Acquisition of a Complete Regional Multiomic Fermentation-Physiology Dataset

    To successfully obtain a complete regional multiomic fermentation-physiology dataset - defined as paired Atmo gas capsule data (H2, CO2, O2), CapScan regional microbiome/fluid sampling, stool microbiome sequencing, and breath testing (H2, CH4, H2S) with serum SCFA measurements - from at least 30 of the 40 enrolled participants (15 healthy, 15 IBS), across both study visits. Primary outcome measure: the number and proportion of enrolled participants from whom a complete multiomic dataset is successfully obtained across both study visits.

    Time frame: up to 12 months

Secondary outcomes

  1. Change in Regional Intestinal Gas Concentrations Following Inulin Challenge

    Regional hydrogen (H2), carbon dioxide (CO2), and oxygen (O2) concentration-time profiles will be measured using the Atmo gas-sensing capsule. Changes in gas concentrations between the low-fiber control visit and the 15 g inulin visit will be compared within participants and between healthy and IBS groups, including regional differences between the small intestine and colon.

    Time frame: Through completion of both study visits, 2 week

  2. Regional Intestinal Microbiome Composition Following Dietary Fiber Challenge

    Microbial composition will be characterized from regional intestinal fluid samples collected using the CapScan capsule and from stool samples. Microbiome profiles will be evaluated across intestinal regions and compared between the low-fiber and inulin visits and between healthy and IBS participants.

    Time frame: Through completion of sample collection, up to 72 hours after each study visit

  3. Change in Breath H2, CH4, and H2S Concentrations Following Inulin Challenge

    Breath hydrogen (H2), methane (CH4), and hydrogen sulfide (H2S) concentrations will be measured every 30 minutes during each 8-hour study visit. Concentration-time profiles will be compared between the low-fiber and inulin visits and between healthy and IBS participants.

    Time frame: 8 hours during each study visit

  4. Change in Serum Short-Chain Fatty Acid Concentrations Following Inulin Challenge

    Serum short-chain fatty acid (SCFA) concentrations will be measured from serial blood samples collected every 30 minutes during each 8-hour study visit. SCFA concentration-time profiles will be compared between the low-fiber and inulin visits and between healthy and IBS participants.

    Time frame: 8 hours during each study visit

  5. Change in Gastrointestinal Symptom Severity Following Inulin Challenge

    Participant-reported gastrointestinal symptoms, including bloating/distention, abdominal pain/cramping, flatulence, nausea, and urgency, will be assessed throughout each study visit. Symptom trajectories will be compared between the low-fiber and inulin visits and between healthy and IBS participants.

    Time frame: 8 hours during study visit

  6. Glucose Response Following Dietary Fiber Challenge

    Continuous glucose monitor (CGM)-derived glucose profiles will be evaluated following the low-fiber and inulin meal challenges. Glucose responses will be compared within participants across study visits and between healthy and IBS groups.

    Time frame: Through CGM monitoring throughout 2 weeks including both study visits.

  7. Atmo Capsule Gastrointestinal Transit Time

    Quantify the gastrointestinal transit time of the Atmo capsule after participant ingestion.

    Time frame: From capsule ingestion through passage, confirmation up to 72 hours after clinic visit.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 24 months is above that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856823
Responsible party
Sean Spencer (Assistant Professor of Medicine, Stanford University) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Roujheen Sabetan, MPH
Contact
rsabetan@stanford.edu
925-963-7021
Jacob T Hizon, BS
Contact
jthizon@stanford.edu
619-874-4562
Sean P Spencer, MD PhD
principal investigator · Stanford University
Michael Fischbach, PhD
study director · Stanford University
Benjamin Good, PhD
study director · Stanford University
Jonas Cremer, PhD
study director · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inulin

Start the discussion